查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗生素抗药性诊断市场:病原体，各技术，各地区的策略和趋势 -附执行顾问指南(2025年～2029年)
市场调查报告书
商品编码
1723117

抗生素抗药性诊断市场:病原体，各技术，各地区的策略和趋势 -附执行顾问指南(2025年～2029年)

Antimicrobial Resistance Diagnostic Markets, Strategies and Trends By Pathogen, By Technology, and By Region with Executive and Consultant Guides. 2025 To 2029
出版日期: | 出版商: Howe Sound Research | 英文 391 Pages | 商品交期: 最快1-2个工作天内

价格

报告概述

为了减轻抗菌素抗药性所带来的威胁，诊断技术正占据主导地位。这些技术能否在新型抗生素出现前解决问题？为了抓住这个不断成长的市场，人们正在开发超越基因定序的新型诊断技术。我们着眼于技术格局，帮助您了解诊断病原体和感染的不同方法。我们已经识别了该领域六种主要病原体的机会并制定了市场预测。我们分析了30家活跃于该领域的大型和小型企业。

利用最新数据进行投资决策与估价。

按本报告提供全球抗生素抗药性诊断市场相关调查，提供市场概要，以及病原体，各技术，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场指南

第2章 简介和市场定义

  • 抗生素抗药性的威胁和机会
  • 机会定义
  • 方法与资讯来源
  • 观点:医疗保健和IVD产业
  • 诊断费

第3章 动态的市场概要

  • 市场进入组织
    • 学术研究机关
    • 诊断测试开发商
    • 测量设备供应商
    • 药品·试剂厂商
    • 病理供应商
    • 独立型临床检验室
    • 公共的国立/地区研究所
    • 医院检验室
    • 临床检验室
    • 审核机关
    • 认证机关
  • 关于抗生素抗药性理解
  • 新抗生素与科技的改变之路
  • AMR的诊断的重要角色

第4章 AMR的市场机会

  • AMR的主要大规模市场机会
  • 诊断技术开发机会

第5章 抗生素抗性诊断最近的趋势

第6章 主要AMR诊断企业

  • 1928 Diagnostics
  • Abbott Laboratories
  • Accelerate Diagnostics
  • ADT Biotech
  • Beckman Coulter Diagnostics(Danaher)
  • Becton, Dickinson and Company
  • Binx Health
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid(Danaher)
  • Curetis(OpGen)
  • Day Zero Diagnostics
  • DeepUII Diagnostics
  • DNAe
  • Enzo Biochem
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • Genetic Signatures
  • Great Basin Scientific, Inc
  • Hologic
  • Hutman Diagnostics
  • Inflammatix
  • Linear Diagnostics
  • Lumos Diagnostics
  • MGI
  • Millipore Sigma
  • OpGen
  • Pathogenomix
  • Qiagen
  • QuidelOrtho
  • Revvity
  • Roche Diagnostics
  • Scope Fluidics
  • SeLux Diagnostics
  • Sherlock Biosciences
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific
  • Uniogen
  • Vela Diagnostics
  • Visby Medical

第7章 全球抗生素抗药性诊断市场

  • 各国全球市场概要
  • 按病原体全球市场- 概要
  • 各技术全球市场- 概要

第8章 全球抗生素抗性诊断市场- 病原体

  • 药物抗性肺炎球菌-DRSP
  • 药物抗性曲状桿菌- 刚果民主共和国
  • 难辨梭状芽孢桿菌-CD
  • 抗药性金黄色葡萄球菌(MRSA)
  • 药物抗性淋菌(DRNG)
  • 药物抗性沙门菌-DRNTS

第9章 全球抗生素抗性诊断市场- 各技术

  • 微生物学培养
  • 免疫检测
  • PCR
  • NGS
  • 质谱分析法
  • 迅速检验和照护现场

第10章 AMR诊断的未来愿景

第11章 附录

Report Overview:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. Will these technologies solve the problem before new antibiotics come along? New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile over 30 companies, large and small, working in this area.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

  • 1.1. Antimicrobial Resistance - Strategic Situation Analysis
  • 1.2. Guide for Executives and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. The Threat and Opportunity of Antimicrobial Resistance
  • 2.2. Defining the Opportunity
    • 2.2.1. Revenue Market Size
  • 2.3. Methods and Sources
    • 2.3.1. Methodology
    • 2.3.2. Sources
    • 2.3.3. Authors
  • 2.4. Perspective: Healthcare and the IVD Industry
    • 2.4.1. Global Healthcare Spending
  • 2.5. Spending on Diagnostics
    • 2.5.1. Important Role of Insurance for Diagnostics

3. Overview of a Dynamic Market

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Diagnostic Test Developer
    • 3.1.2. Instrumentation Supplier
    • 3.1.3. Chemical/Reagent Supplier
    • 3.1.4. Pathology Supplier
    • 3.1.5. Independent Clinical Laboratory
    • 3.1.6. Public National/regional Laboratory
    • 3.1.7. Hospital Laboratory
    • 3.1.8. Physicians Office Lab (POLS)
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body
  • 3.2. Understanding Antimicrobial Resistance
    • 3.2.1. What is Antimicrobial Resistance (AMR)
    • 3.2.2. Bacteria and Other Microbes
    • 3.2.3. The History of Antibiotics
    • 3.2.4. The Role of Animal Husbandry
    • 3.2.5. The Implications of Horizontal Transfer
    • 3.2.6. The Threat of AMR
  • 3.3. The Changing Road to New Antibiotics & Technologies
  • 3.4. The Key Role of Diagnostics in AMR

4. The Market Opportunity of AMR

  • 4.1. The Key Large Market Opportunities in AMR
    • 4.1.1. Streptococcus Pneumoniae (DRSP)
    • 4.1.2. Campylobacter (DRC)
    • 4.1.3. Clostridium Difficile (CD)
    • 4.1.4. Staphylococcus aureus (MRSA)
    • 4.1.5. Neisseria gonorrhoeae (DRNG)
    • 4.1.6. Salmonella (DRNTS)
  • 4.2. Diagnostic Technology Development Opportunities
    • 4.2.1. What's Wrong with Microbiology
    • 4.2.2. The Features Battleground of Infectious Disease Diagnostics
    • 4.2.3. Multiplex vs. POC/Rapid
    • 4.2.4. The Miracle of Genetics
    • 4.2.5. From Multiple Pathogens to All Pathogens - The Next Next Generation
    • 4.2.6. Gene Sequence Diagnostics WITHOUT the Sequencing
    • 4.2.7. Markers of Resistance
    • 4.2.8. What Happens to the Microbiology Lab?

5. Antibiotic Resistance Diagnostics Recent Developments

  • 5.1. Antibiotic Resistance Recent Developments
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. DeepUll Raises Euro-50M in Oversubscribed Round
  • 5.3. BioMerieux Gets Clearance for ID/AST System
  • 5.4. New antibiotics could treat 'super bugs'
  • 5.5. Cepheid, Fleming Partner to Address AMR
  • 5.6. Fuse Dx and Prompt Dx Funded for POC Tests
  • 5.7. FDA Approval for Karius
  • 5.8. Presymptom Health Develops Sepsis Test
  • 5.9. Visby Medical to Develop STI and AMR MDx
  • 5.10. Siemens Healthineers to Develop NGS-Based Sepsis Test
  • 5.11. Researchers Developing POC Test for Detecting Risk SNPs
  • 5.12. Curetis, FIND Extend AMR Research
  • 5.13. Delve Bio to Develop Metagenomic Dx
  • 5.14. BioMerieux, Oxford Nanopore Form ID Dx Pact
  • 5.15. DnaNudge, Mylab Forge Dx Partnership
  • 5.16. FDA Clears New bioMerieux Diagnostic System and Panel
  • 5.17. Selux Diagnostics Phenotyping System Gets FDA Approval
  • 5.18. New diagnostics to tackle drug resistant infections
  • 5.19. Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels
  • 5.20. Three companies join forces to tackle antimicrobial resistance (AMR)
  • 5.21. T2 Biosystems Exercises BARDA Option
  • 5.22. OpGen to Ramp up Use of Acuitas AMR Gene Panel
  • 5.23. BD Partners With Pfizer, Wellcome to Study AMR Dx
  • 5.24. Sepsis Test Developers Accelerate Plans
  • 5.25. OpGen Receives FDA Clearance for AMR Panel
  • 5.26. Visby Medical - Rapid Uptake of Handheld PCR Test for STIs
  • 5.27. MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
  • 5.28. BioMerieux Receives CE Mark for Vitek Clinical Microbiology System
  • 5.29. Hologic to Acquire Mobidiag
  • 5.30. Campylobacter strains exchange genes
  • 5.31. Disinfection spreads antimicrobial resistance
  • 5.32. Molzym, Fraunhofer Developing Rapid Sepsis Dx
  • 5.33. Illumina, IDbyDNA Build NGS-Based Respiratory Panel
  • 5.34. Accelerate Diagnostics Expands AMR Testing
  • 5.35. Rapid diagnostics linked to optimal antibiotics
  • 5.36. Visby Medical Wins AMR Diagnostic Competition
  • 5.37. DNAe Technology SARS-CoV-2 Sequences
  • 5.38. Infections with foodborne bacteria becoming harder to treat
  • 5.39. Dust is sharing antibiotic resistance genes

6. Key AMR Diagnostics Companies

  • 6.1. 1928 Diagnostics
  • 6.2. Abbott Laboratories
  • 6.3. Accelerate Diagnostics
  • 6.4. ADT Biotech
  • 6.5. Beckman Coulter Diagnostics (Danaher)
  • 6.6. Becton, Dickinson and Company
  • 6.7. Binx Health
  • 6.8. bioMerieux Diagnostics
  • 6.9. Bio-Rad Laboratories, Inc.
  • 6.10. Cepheid (Danaher)
  • 6.11. Curetis (OpGen)
  • 6.12. Day Zero Diagnostics
  • 6.13. DeepUII Diagnostics
  • 6.14. DNAe
  • 6.15. Enzo Biochem
  • 6.16. Eurofins Scientific
  • 6.17. Fusion Genomics
  • 6.18. GeneFluidics
  • 6.19. Genetic Signatures
  • 6.20. Great Basin Scientific, Inc
  • 6.21. Hologic
  • 6.22. Hutman Diagnostics
  • 6.23. Inflammatix
  • 6.24. Linear Diagnostics
  • 6.25. Lumos Diagnostics
  • 6.26. MGI
  • 6.27. Millipore Sigma
  • 6.28. OpGen
  • 6.29. Pathogenomix
  • 6.30. Qiagen
  • 6.31. QuidelOrtho
  • 6.32. Revvity
  • 6.33. Roche Diagnostics
  • 6.34. Scope Fluidics
  • 6.35. SeLux Diagnostics
  • 6.36. Sherlock Biosciences
  • 6.37. Siemens Healthineers
  • 6.38. Sysmex
  • 6.39. Thermo Fisher Scientific
  • 6.40. Uniogen
  • 6.41. Vela Diagnostics
  • 6.42. Visby Medical

7. The Global Market for Antimicrobial Resistance Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Technology - Overview
    • 7.2.1. Table - Global Market by Pathogen
    • 7.2.2. Chart - Global Market by Pathogen - Base/End Year Comparison
    • 7.2.3. Chart - Global Market by Pathogen - Base Year
    • 7.2.4. Chart - Global Market by Pathogen - End Year
    • 7.2.5. Chart - Global Market by Pathogen - Share by Year
    • 7.2.6. Chart - Global Market by Pathogen - Segment Growth
  • 7.3. Global Market by Technology - Overview
    • 7.3.1. Table - Global Market by Technology
    • 7.3.2. Chart - Global Market by Technology - Base/End Year Comparison
    • 7.3.3. Chart - Global Market by Technology - Base Year
    • 7.3.4. Chart - Global Market by Technology - End Year
    • 7.3.5. Chart - Global Market by Technology - Share by Year
    • 7.3.6. Chart - Global Market by Technology - Segment Growth

8. Global Antibiotic Resistance Diagnostic Markets - By Pathogen

  • 8.1. Drug Resistant Streptococcus Pneumoniae - DRSP
    • 8.1.1. Table DRSP - by Country
    • 8.1.2. Chart - DRSP Growth
  • 8.2. Drug Resistant Campylobacter - DRC
    • 8.2.1. Table DRC - by Country
    • 8.2.2. Chart - DRC Growth
  • 8.3. Clostridium Difficile - CD
    • 8.3.1. Table CD - by Country
    • 8.3.2. Chart - CD Growth
  • 8.4. Methicillin Resistant Staphylococcus Aureus - MRSA
    • 8.4.1. Table MRSA - by Country
    • 8.4.2. Chart - MRSA Growth
  • 8.5. Drug Resistant Neisseria Gonorrhoeae - DRNG
    • 8.5.1. Table DRNG - by Country
    • 8.5.2. Chart - DRNG Growth
  • 8.6. Drug Resistant Salmonella - DRNTS
    • 8.6.1. Table DRNTS - by Country
    • 8.6.2. Chart - DRNTS Growth

9. Global Antibiotic Resistance Diagnostic Markets - by Technology

  • 9.1. Microbiology Culture
    • 9.1.1. Table Culture - by Country
    • 9.1.2. Chart - Culture Growth
  • 9.2. Immunoassay
    • 9.2.1. Table Immunoassay - by Country
    • 9.2.2. Chart - Immunoassay Growth
  • 9.3. PCR
    • 9.3.1. Table PCR - by Country
    • 9.3.2. Chart - PCR Growth
  • 9.4. NGS
    • 9.4.1. Table NGS - by Country
    • 9.4.2. Chart - NGS Growth
  • 9.5. Mass Spectrometry - MS
    • 9.5.1. Table MS - by Country
    • 9.5.2. Chart - MS Growth
  • 9.6. Rapid and Point of Care - Rapid/POC
    • 9.6.1. Table Rapid/POC - by Country
    • 9.6.2. Chart - Rapid/POC Growth

10. Vision of the Future of AMR Diagnostics

11. Appendices

  • 11.1. United States Medicare System: Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: Known Human Pathogenic Diseases
  • Table 3: The Key Market Opportunities
  • Table 4: Market Potential DRSP Diagnostic
  • Table 5: Market Potential DRC Diagnostic
  • Table 6: Market Potential CD Diagnostic
  • Table 7: Market Potential CD Diagnostic
  • Table 8: Market Potential DRNG Diagnostic
  • Table 9: Market Potential DRNTS Diagnostic
  • Table 10: Key AMR Diagnostics Issues
  • Table 11: Global Market by Region
  • Table 12: Global Market by Pathogen
  • Table 13: Global Market by Technology
  • Table 14: DRSP by Country
  • Table 15: DRC by Country
  • Table 16: CD by Country
  • Table 17: MRSA by Country
  • Table 18: DRNG by Country
  • Table 19: DRNTS by Country
  • Table 20: Culture by Country
  • Table 21: Immunoassay by Country
  • Table 22: PCR by Country
  • Table 23: NGS by Country
  • Table 24: MS by Country
  • Table 25: Rapid/POC by Country
  • Table 26: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Healthcare Spending Map
  • Figure 2: The Lab Test Pie
  • Figure 3: The Road to Diagnostics
  • Figure 4: AMR and Antibiotic Introduction
  • Figure 5: The Death Toll of AMR
  • Figure 6: Global Market Share Chart
  • Figure 7: Global Market by Pathogen - Base vs. End Year
  • Figure 8: Global Market by Pathogen Base Year
  • Figure 9: Global Market by Pathogen End Year
  • Figure 10: Pathogen Share by Year
  • Figure 11: Pathogen Segment Growth
  • Figure 12: Technology - Base vs. End Year Segment Shift
  • Figure 13: Technology Market Base Year
  • Figure 14: Technology Market End Year
  • Figure 15: Technology Share by Year
  • Figure 16: Technology Segment Growth
  • Figure 17: DRSP Growth
  • Figure 18: DRC Diagnostics Growth
  • Figure 19: CD Growth
  • Figure 20: MRSA Growth
  • Figure 21: DRNG Growth
  • Figure 22: DRNTS Growth
  • Figure 23: Culture Growth
  • Figure 24: Immunoassay Growth
  • Figure 25: PCR Growth
  • Figure 26: NGS Growth
  • Figure 27: MS Growth
  • Figure 28: Rapid/POC Growth